Followers | 28 |
Posts | 4308 |
Boards Moderated | 1 |
Alias Born | 09/22/2006 |
Monday, May 06, 2019 10:03:06 AM
Halozyme Therapeutics, Inc. (NASDAQ:HALO
Monday 6 May 2019
SAN DIEGO, May 6, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced the appointment of biotechnology and pharmaceutical industry expert Alison A. Armour, M.B. Ch.B., B.Sc., M.Sc., M.D., FRCR, FRCP, as senior vice president, research and development, effective immediately. In this role, she will report to Dr. Helen Torley, president and chief executive officer.
Dr. Armour will lead Halozyme's research, clinical development, regulatory, safety and pharmacovigilance efforts. Alison's immediate focus will be the PEGPH20 regulatory submissions for pancreas cancer in the event of positive data. She will also play a key role in shaping the PEGPH20 new indication development strategy and expanding our oncology portfolio.
"I am delighted to welcome Alison to Halozyme," said Dr. Torley. "She brings a wealth of experience in all stages of oncology drug development, as well as over 15 years of practice as a clinical oncologist. Her experience and strong record of overseeing successful regulatory submissions makes Alison a valuable addition to our leadership team."
Dr. Armour joins Halozyme from Endocyte, where she served as Chief Medical Officer and was responsible for the company's clinical division, including all medical, clinical operations, regulatory, data management and pharmacovigilance activities. In this position, she worked on all aspects of the company's portfolio, including folate and PSMA and CAR-T therapies. She played a key role in Endocyte's successful in-licensing deal of PSMA617 in 2017 and the subsequent development process that resulted in Endocyte's sale to Novartis for $2.1 billion in December 2018.
Prior to joining Endocyte, Dr. Armour served as Vice President of Development and team lead for TYKERB® at GSK and then at Novartis. Earlier in her career, Dr. Armour also served as global medical science director at AstraZeneca, where she led early, late stage, and post-commercial medical development for IRESSA®, obtaining the first EGFRm+ approval in non-small cell lung cancer (NSCLS) for the drug.
"I am excited to join Halozyme and contribute to its efforts to bring innovative new therapies to the market that can improve patients' lives utilizing my experience in drug development and oncology," said Dr. Armour.
Dr. Armour is known in the industry for her research and her leadership in the areas of medical and radiation oncology—she has co-authored two textbooks and more than 60 publications. Dr. Armour earned her B.Sc. in Biochemistry, her M.B., Ch.B., M.Sc., and Doctorate of Medicine from the University of Glasgow; her FRCR at the Royal College of Radiologists London, UK and her FRCP at the Royal College of Physicians in London, UK, for contributions to the field of oncology.
About Halozyme
The more you know, the less you don't know.
Recent HALO News
- Mahesh Krishnan Elected to Halozyme's Board of Directors • PR Newswire (US) • 04/25/2024 08:45:00 PM
- Halozyme to Report First Quarter 2024 Financial and Operating Results • PR Newswire (US) • 04/23/2024 12:30:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/04/2024 09:13:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/28/2024 11:49:54 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/28/2024 09:07:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 10:12:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 10:05:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 10:01:21 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/27/2024 09:08:09 PM
- Halozyme to Participate in Upcoming Investor Conferences • PR Newswire (US) • 02/27/2024 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2024 11:59:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2024 11:55:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2024 11:53:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2024 11:49:54 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/20/2024 09:07:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 09:03:54 PM
- HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS • PR Newswire (US) • 02/20/2024 09:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 10:47:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 10:41:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 10:39:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 09:18:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 09:15:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 09:12:56 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 11:19:50 AM
- Halozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating Results • PR Newswire (US) • 02/08/2024 09:30:00 PM
FEATURED Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • Apr 25, 2024 8:52 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM